Ethics approval and consent to participate
Cancer
CANCER
Ethical approval was obtained from the Institutional Review Board at Peking University Cancer Hospital’s Ethics Committee (No.2021YJZ109) address: Peking University Cancer Hospital’s Ethics Committee, No. 81 Fucheng Street, Haidian District, Beijing, China. The trial was registered in the Chinese Clinical Trial Registry (ChiCTR2200055180, date of registration: 2022–01-02) prior to patient enrollment. The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. Written informed consent was obtained from all patients.